ClinicalTrials.gg
TerminatedNCT03370601STAMPUpdated Feb 15, 2019

Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases

An interventional study of Infliximab and Mercaptopurine in Inflammatory Bowel Diseases, sponsored by University Hospital, Lille. Terminated at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Not enough recruitment Lack of funding CR

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jan 2017, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies in Inflammatory Bowel Diseases by University Hospital, Lille — 1 open to participants now, 1 under way, none of them phase 3. Inflammatory Bowel Diseases · University Hospital, Lille.

Started
2017
the only one that year
No phase
4 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Inflammatory Bowel Diseases by University Hospital, Lille, this one is the only one that started in 2017, is one of 4 with no phase, and was the 4th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 424 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

1 of the 10 studies in Inflammatory Bowel Diseases by University Hospital, Lille is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 277 Inflammatory Bowel Diseases studies recruiting now, 134 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Inflammatory Bowel Diseases by University Hospital, Lille, or all of them as a file.
02

Study summary

This study evaluates 2 therapeutic strategies (increase infliximab dose or add an immunosuppressant) in patients with inflammatory bowel disease in loss of response to infliximab. Addition of an immunosuppressant may be more efficient at long term and is less expensive.

03

Conditions studied

  • Inflammatory Bowel Diseases

Keywords

  • crohn's disease
  • ulcerative colitis
  • infliximab
  • loss of response
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with ulcerative colitis or crohn's disease
  • treated with infliximab (5mg/kg per 8 weeks) and with loss of response after at least 4 infusions of infliximab
  • active disease ( HBI > 5 for CD patients or SCCAI> 6 for UC patients)
  • patients treated with infliximab only at the time of loss of response

Exclusion criteria

Exclusion Criteria:

  • Patients with CD with ano perineal lesions and without luminal activity
  • patients treated with cortico and having had history of intolerance to azathioprin, 6-mercaptopurine or methotrexate
  • patients with acute severe flare (HBI>12 for CD patients and Lichtiger score > 10 for UC patients)
  • pregnant female
  • patients with anal disease alone
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Other
    Optimisation strategy

    increase of Infliximab dose from 5mg/kg every 8 weeks to Infliximab 10 mg/kg every 8 weeks

    Drug: Infliximab

  • Other
    Addition strategy

    same dose of Infliximab ( 5mg/kg every 8 weeks) with addition of immunosuppressive agent: Azathioprine or Mercaptopurine

    Drug: Mercaptopurine · Drug: Azathioprine · Drug: Infliximab

Interventions

  • Infliximab 10mg/kg every 8 weeks

  • 6-mercaptopurine 1 à 1,5 mg/kg

    Also known as: addition strategy with 6-mercaptopurine in second intention

  • Azathioprine 2 à 2.5mg/kg/j

    Also known as: addition strategy with azathioprine in first intention

  • Infliximab 5mg/kg every 8 weeks

06

What researchers measure

Primary outcomes

  1. Number of patients in Clinical remission

    the clinical remission is defined by Harvey Bradshaw (HBI) Index \< 4 for Crohn's disease or Simple Clinical Colitis Activity Index (SCCAI)\<4 for ulcerative colitis.

    Time frame: At Week 52

Secondary outcomes

  1. Number of patients in deep remission

    clinical remission associated with endoscopic remission (CDEIS \<3 for CD patients or Mayo score\<2 for UC patients)

    Time frame: At Week 52

  2. Number of patient in remission and clinical response

    clinical response is defined as a decrease of at least 3 points of HBI for CD patients or SCCAI for UC patients compared to baseline (week 0). Simple Clinical Colitis Activity Index (SCCAI)\<4 for ulcerative colitisHBI pour MC et SCCAI pour RCH \<4 associated at CRP \< 5 mg/dl.

    Time frame: At week 16

  3. infliximab blood concentration

    Time frame: Baseline, week 16 ad week 52

  4. infliximab antibodies concentration

    Time frame: Baseline, week 16 ad week 52

  5. economic criteria

    medical fees in each arm

    Time frame: At week 52

  6. number of patient with adverse effects and allergic reactions with infliximab

    Time frame: At week 52

  7. Inflammatory bowel disease questionnaire (score IBDQ)

    quality of life

    Time frame: Baseline and week 52

07

Study locations

1 site
  • CHRU, Hôpital Claude Huriez
    Lille, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Jan 2019, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2017
First posted
Dec 12, 2017
StartActual
Jan 3, 2017
Primary completionActual
Jan 2019
CompletionActual
Jan 2019
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03370601
Responsible party
Sponsor
First posted
Dec 12, 2017
Start date
Jan 3, 2017
Primary completion
Jan 2019
Completion
Jan 2019
Last update
Feb 15, 2019

Study contacts

Benjamin Pariente, MD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion